🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the battle against superbug strains of the infection, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are on the rise worldwide, with figures suggesting more than 82 million infections annually. Notably increased rates are reported in the African continent and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the face of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices currently available.”

Health officials are increasingly worried about the rise in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring showed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, marketed under the name a brand name, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, gained clearance in the same week. This treatment, which is also used to treat UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The charitable organization GARDP worked alongside the drug firm its industry partner to see it through.

“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

According to data published in a prominent scientific publication, the new drug cured over nine in ten of uncomplicated infections. This establishes an equal footing with the current standard treatment, which involves two antibiotics. The study involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the ability to make available and distribute the drug in numerous developing nations.

Clinicians on the front lines have expressed optimism. The availability of a easy-to-administer therapy of this kind is hailed as a "critical tool" for gonorrhoea control. This is viewed as vital to lessen the impact of the infection for people and to stop the proliferation of untreatable gonorrhoea worldwide.